Pi Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Pi Therapeutics General Information

Description

Operator of a preclinical-stage pharmaceutical company intended to develop protein degradation modulators for the treatment of cancer. The company offers a unique approach to the preferential targeting of cancer cells as well as develop a proprietary cancer drug that inhibits the proteasome-interacting protein Rpn13, enabling people to access proper treatment of cancer.

Contact Information

Website
www.pi-therapeutics.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 2 Ilan Ramon street
  • Ness Ziona 7403635
  • Israel
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 2 Ilan Ramon street
  • Ness Ziona 7403635
  • Israel

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pi Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 24-Sep-2021 Completed Out of Business
4. Early Stage VC (Series B) 29-May-2019 Completed Generating Revenue
3. Seed Round Completed Pre-Clinical Trials
2. Accelerator/Incubator 01-Mar-2015 Completed Pre-Clinical Trials
1. Accelerator/Incubator 12-Dec-2014 Completed Pre-Clinical Trials
To view Pi Therapeutics’s complete valuation and funding history, request access »

Pi Therapeutics Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

Pi Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019232661-A1 Compounds for inhibiting protein degradation and methods of use thereof in the treatment of cancer Inactive 08-Mar-2018
CA-3092797-A1 Compounds for inhibiting protein degradation and methods of use thereof in the treatment of cancer Inactive 08-Mar-2018
EP-3762366-A1 Compounds for inhibiting protein degradation and methods of use thereof in the treatment of cancer Inactive 08-Mar-2018
US-20200399262-A1 Compounds for inhibiting protein degradation and methods of use thereof in the treatment of cancer Inactive 08-Mar-2018
WO-2019171379-A1 Compounds for inhibiting protein degradation and methods of use thereof in the treatment of cancer Inactive 08-Mar-2018 C07D413/14
To view Pi Therapeutics’s complete patent history, request access »

Ready to get started?

Request a free trial

Pi Therapeutics FAQs

  • When was Pi Therapeutics founded?

    Pi Therapeutics was founded in 2014.

  • Where is Pi Therapeutics headquartered?

    Pi Therapeutics is headquartered in Ness Ziona, Israel.

  • What industry is Pi Therapeutics in?

    Pi Therapeutics’s primary industry is Drug Discovery.

  • Is Pi Therapeutics a private or public company?

    Pi Therapeutics is a Private company.

  • What is Pi Therapeutics’s current revenue?

    The current revenue for Pi Therapeutics is .

  • How much funding has Pi Therapeutics raised over time?

    Pi Therapeutics has raised $19.7M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process